{"id":152473,"date":"2025-03-23T22:31:25","date_gmt":"2025-03-23T22:31:25","guid":{"rendered":"https:\/\/peraltafinancing.com\/business\/finance\/abbvie-stock-surges-as-it-enters-the-booming-weight-loss-market\/"},"modified":"2025-03-23T22:31:25","modified_gmt":"2025-03-23T22:31:25","slug":"abbvie-stock-surges-as-it-enters-the-booming-weight-loss-market","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=152473","title":{"rendered":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"articlecontent\">\n<div class=\"content-module \" data-content-module=\"CompanyOverview\" data-company=\"NYSE:ABBV\">\n<div class=\"alignleft bg-white border rounded\" style=\"width:350px;max-width:100%\">\n<div class=\"p-2 p-md-3\">\n<h3 class=\"section-h h6 mt-0 mb-3 pt-0\">AbbVie Today<\/h3>\n<div class=\"d-flex mb-1\">\n<div class=\"py-2 pr-2 mr-2 text-center company-thumbnail border-right mb-1\" style=\"width:55px\"><img decoding=\"async\" loading=\"lazy\" height=\"9\" width=\"55\" src=\"https:\/\/www.marketbeat.com\/logos\/thumbnail\/abbvie-inc-logo.jpg\" alt=\"AbbVie Inc. stock logo\"\/><\/div>\n<\/div>\n<div class=\"d-inline-block mb-2 mr-4\"><strong style=\"font-size:1.7rem;color: var(--blue-11);\">$209.98<\/strong> <strong style=\"color:#D2333D\"> -1.98\u00a0(-0.94%)<\/strong> <\/p>\n<div class=\"price-updated\">As of 03\/21\/2025 03:59 PM Eastern <\/p>\n<div class=\"inline-always-moreinfo moreinfo bg-white\" tabindex=\"0\"><span class=\"fa-regular fa-circle-info c-gray\" aria-hidden=\"true\"\/><span style=\"font-size:.8rem;width:170px;\" class=\"tooltiptext\" id=\"tooltip-fmv\">This is a fair market value price provided by Polygon.io. <a href=\"http:\/\/www.marketbeat.com\/about\/#data\">Learn more.<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<dl>\n<div class=\"price-data w-range\">\n<dt class=\"range-label\">52-Week Range<\/dt>\n<dd class=\"range-meter\">$153.58<\/p>\n<p><span class=\"range-marker\" style=\"left:87%\"><span class=\"range-arrow\">\u25bc<\/span><\/span><\/p>\n<p>$218.66<\/dd>\n<\/div>\n<p><dt>Dividend Yield<\/dt>\n<dd><strong>3.12%<\/strong><\/p>\n<dd\/><\/dd>\n<\/p>\n<p><dt>P\/E Ratio<\/dt>\n<dd><strong>87.49<\/strong><\/dd>\n<\/p>\n<p><dt>Price Target<\/dt>\n<dd><strong>$211.45<\/strong><\/dd>\n<\/p>\n<\/dl>\n<\/div>\n<\/div>\n<\/div>\n<p><a href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/ABBV\/\" target=\"_blank\" rel=\"noreferrer noopener\">AbbVie Inc. <span class=\"hoverDetails\" data-prefix=\"NYSE\" data-symbol=\"ABBV\">NYSE: ABBV<span class=\"saved-tooltiptext d-none\"\/><\/span><\/a> is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement pertains to Gubra\u2019s experimental weight loss drug, which is in a Phase 1 trial.<\/p>\n<p>AbbVie paid Gubra a $350 million upfront payment for the right to its experimental weight loss drug, GUB014295, which is in a Phase 1 trial. AbbVie has committed to paying Gubra up to $1.9 billion based on certain development and sales milestones that are met.<\/p>\n<div class=\"mb-4 mx-0 row border-top border-bottom pr-2 py-2 align-items-center\" style=\"font-size:1rem; border-color:var(--gray-4);clear:both;\">\n<p><label for=\"InPostRegistrationEmail\" class=\"w-100 p-1 d-flex flex-wrap justify-content-start align-items-center mb-0 c-blue font-small\"><span class=\"fa-regular fa-bullhorn mr-2\"\/><span style=\"line-height:1em;\">Get <strong>AbbVie<\/strong> alerts:<\/span><\/label><\/p>\n<p><input id=\"InPostRegistrationEmail\" name=\"RegisterEmail\" type=\"text\" placeholder=\"Enter Your Email Address\" class=\"col-12 col-sm-8 m-0 mb-1 mb-sm-0 top-labeled-input font-small\"\/><button id=\"signUpButton\" type=\"button\" class=\"btn btn-featured col-12 col-sm-4\" style=\"margin:0!important;border:none!important\">Sign Up<\/button><\/p>\n<\/div>\n<p>But the move higher after this announcement just continues the bullish pattern in place with ABBV stock, which has been up more than 19% since the start of the year. Analyst sentiment suggests the stock still has room to run higher.<\/p>\n<h2><strong>How Gubra Is Different From Existing Competition<\/strong><\/h2>\n<p>Entering the weight loss market makes sense for AbbVie when you consider that analysts believe the weight loss drug market could be worth $130 billion by 2030. Currently <a href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/NVO\/\" target=\"_blank\" rel=\"noreferrer noopener\">Novo Nordisk A\/S <span class=\"hoverDetails\" data-prefix=\"NYSE\" data-symbol=\"NVO\">NYSE: NVO<span class=\"saved-tooltiptext d-none\"\/><\/span><\/a> with Ozempic and <a href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/LLY\/\" target=\"_blank\" rel=\"noreferrer noopener\">Eli Lilly and Co. <span class=\"hoverDetails\" data-prefix=\"NYSE\" data-symbol=\"LLY\">NYSE: LLY<span class=\"saved-tooltiptext d-none\"\/><\/span><\/a> with Zepbound are the major players. And like those two drugs, GUB014295 (also known as GUBamy) is an injectable drug.<\/p>\n<p>But it\u2019s important to note that GUBamy offers a distinct difference that Gubra believes will be an advantage. Both Ozempic and Zepbound target the GLP-1 hormone. By contrast, GUBamy acts as an analog of the body\u2019s amylin hormone.<\/p>\n<p>Amylin has been identified as a potential therapeutic target for obesity treatment. The hormone gives patients\u2019 brains a feeling of fullness that helps suppress appetite, reduce food intake, and delays gastric emptying. The optimism is that GUBamy may provide a more long-lasting solution to weight management. In results from Gubra\u2019s six-week Phase 1 study in 2024, patients achieved 3% weight loss after a single dose.<\/p>\n<h2><strong>It\u2019s Not Who\u2019s Selling, It\u2019s Who\u2019s Buying<\/strong><\/h2>\n<p>In February, the <a href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/ABBV\/insider-trades\/\" target=\"_blank\" rel=\"noreferrer noopener\">AbbVie Insider Trades on MarketBeat<\/a> show three different AbbVie executives sold the company\u2019s stock in February. Retail investors frequently assign too much importance when company insiders sell stock. In this case, each trade was executed pursuant to a Rule 10b5-1 plan.<\/p>\n<p>A Rule 10b5-1 plan is a written agreement between a corporate insider and a broker, establishing predetermined trading instructions with a predetermined share price, amount, and transaction date. In each case, these plans were made in November 2024.<\/p>\n<p>It\u2019s a good reminder that investors, even corporate insiders, sell stock for a variety of reasons. But there\u2019s usually only one reason they\u2019re buying. And in the last 12 months, six different members of Congress have bought ABBV stock. And as investors know, Congressional trading doesn\u2019t have the same oversight as a Rule 10b5-1 plan when it comes to potential insider trading.<\/p>\n<h2><strong>Analysts Are Raising Their Price Targets<\/strong><\/h2>\n<div class=\"content-module \" data-content-module=\"DividendStats\" data-company=\"NYSE:ABBV\">\n<div class=\"alignleft\">\n<div class=\"p-2 p-md-3 bg-white border rounded\">\n<h3 class=\"section-h h6 mt-0 mb-2 pt-0\">AbbVie Dividend Payments<\/h3>\n<dl class=\"mb-2\">\n<p><dt>Dividend Yield<\/dt>\n<dd class=\"m-0\"><strong>3.12%<\/strong><\/dd>\n<\/p>\n<p><dt>Annual Dividend<\/dt>\n<dd class=\"m-0\"><strong>$6.56<\/strong><\/dd>\n<\/p>\n<p><dt>Dividend Increase Track Record<\/dt>\n<dd class=\"m-0\"><strong>53 Years<\/strong><\/dd>\n<\/p>\n<p><dt>Annualized 3-Year Dividend Growth<\/dt>\n<dd class=\"m-0\"><strong>6.04%<\/strong><\/dd>\n<\/p>\n<p><dt>Dividend Payout Ratio<\/dt>\n<dd class=\"m-0\"><strong>273.33%<\/strong><\/dd>\n<\/p>\n<p><dt>Next Dividend Payment<\/dt>\n<dd class=\"m-0\"><strong>May. 15<\/strong><\/dd>\n<\/p>\n<\/dl>\n<p><a class=\"upper-link float-right nounderline\" href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/ABBV\/dividend\/\">ABBV Dividend History<\/a><\/div>\n<\/div>\n<\/div>\n<p>Since the announcement in early March, AbbVie stock reached an all-time high at over $216 per share. The stock has fallen back to around $212 as of this writing, and some investors are concerned about the stock\u2019s trailing twelve-month price-to-earnings (P\/E) ratio, which is 88x.<\/p>\n<p>However, AbbVie\u2019s forward P\/E is only around 17x, which is slightly below the company\u2019s ten-year average of around 20x. That suggests that rather than being expensive, ABBV stock may be trading at a discount to its historical average and the average of other stocks in the <a href=\"https:\/\/www.marketbeat.com\/stocks\/sectors\/medical\/\">biopharmaceutical and medical sector<\/a>.\u00a0<\/p>\n<p>That seems to be the <a href=\"https:\/\/www.marketbeat.com\/stocks\/NYSE\/ABBV\/forecast\/\" target=\"_blank\" rel=\"noreferrer noopener\">consensus of the analyst community<\/a>. Since the announcement of the deal with Gubra, two analyst firms, Bank of America and Wells Fargo, have raised their price targets on ABBV stock to $223 and $240, respectively. Erste Group Bank upgraded the stock to a Strong Buy.<\/p>\n<p>Investors looking to get involved will want to see if other analysts raise their outlook before AbbVie reports earnings in April. Even if you feel the stock is too expensive, you may want to consider starting a position simply to collect the company\u2019s dividend, which currently pays $6.56 per share annually.<\/p>\n<p>Before you consider AbbVie, you&#8217;ll want to hear this.<\/p>\n<p>MarketBeat keeps track of Wall Street&#8217;s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the <a href=\"https:\/\/www.marketbeat.com\/newsletter\/PDFoffer.aspx?offer=top5&amp;RegistrationCode=ArticlePage-ShouldYouInvest\">five stocks<\/a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on&#8230; and AbbVie wasn&#8217;t on the list.<\/p>\n<p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.<\/p>\n<p><a class=\"btn btn-featured\" style=\"text-decoration:none\" href=\"https:\/\/www.marketbeat.com\/newsletter\/PDFoffer.aspx?offer=top5&amp;RegistrationCode=ArticlePage-ShouldYouInvest\">View The Five Stocks Here <span class=\"mr-3 fa-regular fa-angle-right\" aria-hidden=\"true\"\/><\/a><\/p>\n<div class=\"mt-4 pt-2 mb-3\">\n<div class=\"bg-light-blue rounded\">\n<div class=\"row align-content-center justify-content-center \">\n<div class=\"col-12 col-sm-4 col-md-3 position-relative pr-sm-0 pb-1 d-flex justify-content-center align-items-start\"><img loading=\"lazy\" decoding=\"async\" height=\"209\" width=\"170\" class=\"mt-2 position-relative\" src=\"https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/max-width:100%;height:auto;z-index:1;margin-top:-0.75em!important;\" alt=\"The Next 7 Blockbuster Stocks for Growth Investors Cover\"\/><\/div>\n<div class=\"col-12 col-sm-8 col-md-9 px-0 pr-sm-3 pl-sm-0\">\n<div class=\"p-4 p-sm-3 h-100 text-center text-sm-left\">\n<p class=\"font-small mb-2\" style=\"line-height:1.3em;\">Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.<\/p>\n<p><a class=\"upper-link\" style=\"text-decoration:none; color:var(--blue); font-size:1rem;\" href=\"https:\/\/marketbeat.com\/newsletter\/pdfoffer.aspx?offer=thenext7blockbusterstocksforgrowthinvestors&amp;RegistrationCode=ArticlePage-FreeReport\">Get This Free Report<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n<div>\n<p>Like this article? Share it with a colleague.<\/p>\n<p>                    <a title=\"Share on Facebook\" href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/\" target=\"_blank\" rel=\"nofollow noopener\" class=\"btn btn-share\"><span class=\"fa-brands fa-facebook-f\"\/><\/a><a title=\"Share on Twitter\" href=\"https:\/\/twitter.com\/intent\/tweet?text=AbbVie+Stock+Boosts+Portfolios+With+Entry+Into+Weight+Loss+Market%20%24ABBV%20%23ABBV%20https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/\" target=\"_blank\" rel=\"nofollow noopener\" class=\"btn btn-share\"><span class=\"fa-brands fa-x-twitter\"\/><\/a><a title=\"Share on LinkedIn\" onclick=\"window.open('https:\/\/www.linkedin.com\/cws\/share?mini=true&amp;url=https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/', 'name','width=600,height=600')\" href=\"https:\/\/www.linkedin.com\/cws\/share?mini=true&amp;url=https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/\" target=\"popup\" rel=\"nofollow noopener\" class=\"btn btn-share\"><span class=\"fa-brands fa-linkedin-in\"\/><\/a><a title=\"Share on StockTwits\" href=\"https:\/\/api.stocktwits.com\/widgets\/share?via=MarketBeat&amp;body=AbbVie+Stock+Boosts+Portfolios+With+Entry+Into+Weight+Loss+Market%20https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/\" target=\"_blank\" rel=\"nofollow noopener\" class=\"btn btn-share\"><span class=\"fa-kit fa-stocktwits-mark\"\/><\/a><a title=\"Print this page\" href=\"https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/javascript:window.print()\" class=\"btn btn-share\"><span class=\"fa-regular fa-print\"\/><\/a><a title=\"Email this page\" href=\"mailto:?subject=AbbVie%20Stock%20Boosts%20Portfolios%20With%20Entry%20Into%20Weight%20Loss%20Market&amp;body=Check%20out%20this%20stock%3A%20https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/%0D%0A%0D%0AFor%20real-time%20financial%20news%20and%20analysis%2C%20visit%20https%3A%2F%2Fwww.marketbeat.com%2F%20.\" class=\"btn btn-share\"><span class=\"fa-regular fa-envelope\"\/><\/a><a title=\"Copy the URL of this page to the clipboard\" href=\"https:\/\/www.marketbeat.com\/originals\/abbvie-stock-boosts-portfolios-with-entry-into-weight-loss-market\/\" class=\"btn btn-share shareCopy\"><span class=\"fa-regular fa-link\"\/><\/a><\/p>\n<p>Link copied to clipboard.<\/p>\n<\/p><\/div>\n<p><script async src=\"\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n<br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Today $209.98 -1.98\u00a0(-0.94%) As of 03\/21\/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. 52-Week Range $153.58 \u25bc $218.66 Dividend Yield 3.12% P\/E Ratio 87.49 Price Target $211.45 AbbVie Inc. NYSE: ABBV is trading near an all-time high after the company announced a licensing agreement with Gubra, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":152474,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[93],"tags":[63459,27663,10882,8681,11209,3310,13521,1337],"dealstore":[],"offerexpiration":[],"class_list":["post-152473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-abbvie","tag-booming","tag-enters","tag-loss","tag-market","tag-stock","tag-surges","tag-weight"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=152473\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"AbbVie Today $209.98 -1.98\u00a0(-0.94%) As of 03\/21\/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. 52-Week Range $153.58 \u25bc $218.66 Dividend Yield 3.12% P\/E Ratio 87.49 Price Target $211.45 AbbVie Inc. NYSE: ABBV is trading near an all-time high after the company announced a licensing agreement with Gubra, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=152473\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-23T22:31:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"596\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=152473#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"AbbVie Stock Surges as It Enters the Booming Weight Loss Market\",\"datePublished\":\"2025-03-23T22:31:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473\"},\"wordCount\":866,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png\",\"keywords\":[\"AbbVie\",\"booming\",\"enters\",\"Loss\",\"Market\",\"STOCK\",\"Surges\",\"WEIGHT\"],\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=152473#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=152473\",\"url\":\"https:\/\/fivemor.com\/?p=152473\",\"name\":\"AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png\",\"datePublished\":\"2025-03-23T22:31:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=152473#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=152473\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=152473#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png\",\"width\":1200,\"height\":596},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=152473#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Stock Surges as It Enters the Booming Weight Loss Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=152473","og_locale":"en_US","og_type":"article","og_title":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network","og_description":"AbbVie Today $209.98 -1.98\u00a0(-0.94%) As of 03\/21\/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. 52-Week Range $153.58 \u25bc $218.66 Dividend Yield 3.12% P\/E Ratio 87.49 Price Target $211.45 AbbVie Inc. NYSE: ABBV is trading near an all-time high after the company announced a licensing agreement with Gubra, [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=152473","og_site_name":"Som2ny Network","article_published_time":"2025-03-23T22:31:25+00:00","og_image":[{"width":1200,"height":596,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=152473#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=152473"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market","datePublished":"2025-03-23T22:31:25+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=152473"},"wordCount":866,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=152473#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png","keywords":["AbbVie","booming","enters","Loss","Market","STOCK","Surges","WEIGHT"],"articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=152473#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=152473","url":"https:\/\/fivemor.com\/?p=152473","name":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=152473#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=152473#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png","datePublished":"2025-03-23T22:31:25+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=152473#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=152473"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=152473#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/03\/med_20250320132940_abbvie-stock-boosts-portfolios-with-entry-into-wei.png","width":1200,"height":596},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=152473#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"AbbVie Stock Surges as It Enters the Booming Weight Loss Market"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/152473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=152473"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/152473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/152474"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=152473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=152473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=152473"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=152473"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=152473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}